What Documents Should Be Included in a Peptide API Technology Transfer Package

When a peptide API moves from a supplier's site to a buyer's facility, the technology transfer package defines what knowledge travels with the product. Procurement and QA staff should know what documents should be included in a peptide API technology transfer package before signing off on a transfer plan. A complete package supports reproducible manufacturing, analytical method transfer, and a clean regulatory narrative without relying on undocumented know-how.

The core of the package is a process description covering the synthetic route, resin loading, coupling and deprotection strategy, cleavage conditions, and purification steps. This should be written at a level detailed enough for a receiving site to understand critical process parameters and their proven acceptable ranges. Ask whether the description reflects the current validated process or an earlier version, and confirm how deviations observed during development were resolved.

Analytical method transfer documents are equally important. Request the methods for purity by HPLC, identity by mass spectrometry, counter-ion content, water content, and residual solvents, together with system suitability criteria and representative chromatograms. Clarify which methods are compendial and which are supplier-developed. If a method is proprietary, the package should state how the receiving lab will be qualified to run it.

Specifications and justifications belong in the package. QA reviewers should see the release specification, the rationale behind each limit, and any historical data supporting them. This is not the same as a certificate of analysis; it explains why the specification exists. Confirm that the specification version in the package matches the one in the current quality agreement and the regulatory filing.

Stability information should accompany the transfer. Include the stability protocol, available time-point data, storage conditions, and any trends observed in purity or impurities. Procurement teams should note whether the receiving site will need to start its own stability program and whether the supplier will share historical data to support it. This affects timelines and cost more than many buyers expect.

Impurity profiles deserve specific attention. The package should identify known impurities, their origin in the synthetic route, and the control strategy for each. For complex peptides, this may include deletion sequences, truncated fragments, diastereomers, and oxidation products. QA should confirm that the impurity discussion is consistent with the analytical methods and the release specification.